盈康生命(300143) - 2025 Q3 - 季度财报

Revenue and Profitability - The company's revenue for Q3 2025 reached ¥514,808,385, representing a 27.27% increase compared to ¥404,486,660 in the same period last year[4]. - Net profit attributable to shareholders was ¥25,011,711, a decrease of 9.85% from ¥27,743,511 in the previous year[4]. - Basic earnings per share decreased by 23.29% to ¥0.0336 from ¥0.0438 in the same period last year[5]. - Total operating revenue for the current period reached ¥1,357,762,551.29, an increase of 10.6% compared to ¥1,227,709,136.74 in the previous period[29]. - Net profit for the current period was ¥93,807,045.54, representing a 12.5% increase from ¥83,199,781.04 in the previous period[30]. - Earnings per share (EPS) for the current period was ¥0.1168, compared to ¥0.1298 in the previous period, indicating a decrease of 8.2%[31]. - The total comprehensive income for the current period was ¥93,895,819.28, compared to ¥83,135,409.36 in the previous period, indicating a growth of 12.5%[31]. Assets and Liabilities - Total assets increased by 20.37% to ¥4,257,327,588.46 from ¥3,536,733,888.57 at the end of the previous year[5]. - The company reported a total asset of CNY 4,257,327,588.46 as of September 30, 2025, an increase from CNY 3,536,733,888.57 at the beginning of the period[25]. - The company’s total liabilities amounted to CNY 1,835,286,010.02, up from CNY 1,774,670,349.86, reflecting an increase of about 3.2%[26]. - Total liabilities increased to ¥1,640,439,218.11 from ¥1,058,411,535.22, marking a rise of 55%[27]. - Current liabilities due within one year increased by 179.11% to ¥71,898,137.89, primarily due to the leasing of the Guangci Phase II building[12]. - Long-term borrowings rose by 205.44% to ¥466,107,484.50, mainly attributed to increased acquisition loans[12]. Cash Flow and Investments - The company’s cash flow from operating activities showed a slight increase of 0.33% to ¥247,729,500 from ¥246,904,100[5]. - Cash generated from operating activities was ¥1,404,151,215.96, compared to ¥1,281,039,988.86 in the previous period, reflecting a growth of 9.6%[32]. - Total cash inflow from investment activities was $522.90 million, significantly higher than $275.19 million in the prior period, representing an increase of 90.00%[33]. - Cash outflow from investment activities totaled $1.12 billion, up from $699.19 million, indicating a rise of 60.00%[33]. - Net cash flow from financing activities was $184.85 million, compared to $58.36 million in the previous period, showing an increase of 216.00%[33]. - Cash received from investments was $522.81 million, a notable increase from $271.99 million, representing a growth of 92.00%[33]. Equity and Shareholder Information - The company’s total equity attributable to shareholders rose by 3.87% to ¥2,524,691,985.61 from ¥2,430,580,107.07[5]. - Minority interests increased by 93.11% to ¥92,196,384.74, primarily due to the consolidation of Changsha Kexin[12]. - The company had a total of 19,839 common shareholders at the end of the reporting period[14]. - The largest shareholder, Qingdao Yinkang Medical Investment Co., Ltd., holds 49.61% of the shares, totaling 371,782,549 shares[14]. Expenses and Taxation - Total operating costs amounted to ¥1,224,176,374.67, up from ¥1,121,158,642.67, reflecting a growth of 9.2%[29]. - Total tax and additional charges increased by 44.63% to ¥3,934,951.01, primarily due to higher stamp duty and property tax[12]. - Financial expenses rose by 85.13% to ¥4,822,293.98, mainly due to increased long-term borrowings[12]. - Research and development expenses for the current period were ¥32,062,692.84, a decrease of 13% from ¥36,844,629.34 in the previous period[30]. Goodwill and Other Assets - Goodwill increased by 45.91% to ¥1,011,564,085.90 due to the acquisition of Changsha Kexin[11]. - The company’s goodwill rose significantly to CNY 1,011,564,085.90 from CNY 693,292,987.91, indicating an increase of about 45.8%[26]. - The company experienced a 201.83% increase in other receivables, reaching ¥117,456,775.68 from ¥38,914,515.15[11]. Financial Condition and Future Outlook - The company’s financial condition is expected to improve following the approval of the plan to use surplus reserves to cover losses, which is aimed at enhancing investor returns and protecting the rights of minority shareholders[19]. - The company plans to use CNY 1,457,808,920.00 from its surplus reserves and capital reserves to offset accumulated losses, which will reduce surplus reserves to CNY 0[20][21].